144 results on '"Spyridis, N."'
Search Results
2. Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia
- Author
-
Tsirigotis, P, Liga, M, Gkirkas, K, Stamouli, M, Triantafyllou, E, Marangos, M, Pessach, I, Sarantopoulos, A, Spyridis, N, and Spyridonidis, A
- Published
- 2017
- Full Text
- View/download PDF
3. Colonization of High-Risk Children with Carbapenemase-Producing Enterobacteriaceae in Greece
- Author
-
Mougkou, K., Michos, A., Spyridopoulou, K., Daikos, G. L., Spyridis, N., Syriopoulou, V., and Zaoutis, T.
- Published
- 2013
- Full Text
- View/download PDF
4. PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
- Author
-
Gavriilaki, E., primary, Papalexandri, A., additional, Mallouri, D., additional, Batsis, I., additional, Vardi, A., additional, Bousiou, Z., additional, Demosthenous, C., additional, Panteliadou, A., additional, Spyridis, N., additional, Karavalakis, G., additional, Touloumenidou, T., additional, Masmanidou, M., additional, Pistiolas, G., additional, Mouladeniou, F., additional, Vadikoliou, C., additional, Lalayanni, C., additional, Yannaki, E., additional, Anagnostopoulos, A., additional, and Sakellari, I., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors
- Author
-
Dimopoulou, D. Spyridis, N. Vartzelis, G. Tsolia, M.N. Maritsi, D.N.
- Published
- 2022
6. Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data
- Author
-
Bielicki, Julia A., Sharland, Mike, Johnson, Alan P., Henderson, Katherine L., Cromwell, David A., Berger, C., Esposito, S., Danieli, E., Tenconi, R., Folgori, L., Bernaschi, P., Santiago, B., Saavedra, J., Cercenado, E., Brett, A., Rodrigues, F., Cizman, M., Jazbec, J., Babnik, J., Pavčnik, Maja, Pirš, M., Premrov, M. Mueller, Lindner, M., Borte, M., Lippmann, N., Schuster, V., Thürmer, A., Lander, F., Elias, J., Liese, J., Durst, A., Weichert, S., Schneider, C., Hufnagel, M., Rack, A., Hübner, J., Dubos, F., Lagree, M., Dessein, R., Tissieres, P., Cuzon, G., Gajdos, V., Doucet-Populaire, F., Usonis, V., Gurksniene, V., Bernatoniene, G., Tsolia, M., Spyridis, N., Lebessi, E., Doudoulakakis, A., Kyriakou, A., Lutsar, I., Kõljalg, S., Schülin, T., and Warris, A.
- Published
- 2016
- Full Text
- View/download PDF
7. Variation in paediatric hospital antibiotic guidelines in Europe
- Author
-
Spyridis, N, Syridou, G, Goossens, H, Versporten, A, Kopsidas, J, Kourlaba, G, Bielicki, J, Drapier, N, Zaoutis, T, Tsolia, M, Sharland, M, Vergison, A, Léon, V, Delestrait, M, Huza, C, Lepage, P, Mahieu, L, Boy, T, Jansens, H, Van der Linden, D, Briquet, C, Allegaert, K, Smits, A, Gabriels, P, Vuye, A, Lutsar, I, Tamm, E, Larionova, A, Laan, D, Orbach, M, Lorrot, M, Angoulvant, F, Prot-Labarthe, S, Dubos, F, Lagree, M, Hufnagel, M, Schuster, K, Henneke, P, Roilides, E, Iosifidis, E, Corovessi, V, Michos, A, Galanakis, E, Gkentzi, D, Giacquinto, C, Longo, G, Dona, D, Mion, T, DʼArgenio, P, Degli, ML Ciofi, De Luca, M, Ciliento, G, Esposito, S, Danieli, E, Montinaro, V, Tenconi, R, Nicolini, G, Sviestina, C I Montagnani, Pavare, J, Rasnaca, K, Gardovska, D, Grope, I, Usonis, V, Gurksniene, V, Eidukaite, A, Biver, A, Brett, A, Esteves, I, Cambrea, SC, Craiu, M, Tomescu, E, Cizman, M, Babnik, J, Kenda, R, Vidmar, I, Nunez-Cuadros, E, Rojo, P, Lopez-Varela, E, Ureta, N, Mosqueda, R, Perez-Lopez, A, Orta, L, Santos, M, Navarro, M, Santiago, B, Hernandez-Sampelaya, T, Saavedra, J, Pineiro, R, Torel, P, Mate Cano, I, Baumann, P, Berger, C, Menson, E, Botgros, A, Doerholt, K, Drysdale, S, Makwana, N, McCorry, A, Garbash, EM, Chetcutiganado, C, McLeod, M, Caldwell, N, Nash, C, McCullagh, B, Sharpe, D, Tweddell, L, Liese, JG, Aston, J, Gallagher, A, Satodia, P, Howard-Smith, N, Korinteli, I, Tavchioska, G, Jensen, L, Trethon, A, Unuk, S, Childs, N, and Canlas, J
- Published
- 2016
- Full Text
- View/download PDF
8. Changes in clinical indications for community antibiotic prescribing for children in the UK from 1996 to 2006: will the new NICE prescribing guidance on upper respiratory tract infections just be ignored?
- Author
-
Thompson, P.L., Spyridis, N., Sharland, M., Gilbert, R.E., Saxena, S., Long, P.F., Johnson, A.P., and Wong, I.C.K.
- Subjects
Respiratory tract infections -- Care and treatment ,Drug therapy -- Standards ,Practice guidelines (Medicine) -- Usage ,Drugs -- Prescribing ,Drugs -- Standards - Published
- 2009
9. Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children
- Author
-
Eleftheriou, I. Dasoula, F. Dimopoulou, D. Lebessi, E. Serafi, E. Spyridis, N. Tsolia, M.
- Abstract
Rapid antigen detection (RAD) tests for the detection of SARS-CoV-2 are simpler, faster, and less expensive than the reverse-transcription polymerase chain reaction (RT-PCR) that is currently considered the gold standard for the diagnosis of coronavirus disease 2019 (COVID-19). The objective of this study was to determine the performance of the PANBIO COVID-19 Ag RAD (Abbott) test, a lateral flow immunoassay that detects the nucleocapsid protein, using as a reference RT-PCR method the Cobas®8800 System (Roche Diagnostics). This prospective study was conducted in a tertiary Children's Hospital and included individuals aged ≤16 years with COVID-19-related symptoms or epidemiological criteria for COVID-19. Two nasopharyngeal samples were collected to perform the PANBIO RAD test and RT-PCR. Of 744 children included, 51 (6.86%) had a positive RT-PCR result. The RAD test detected 42 of 51 PCR-positive children while there were no false-positive results. The overall sensitivity and specificity were 82.35% (95% CI, 71.9%–92.8%) and 100%, respectively. Sensitivity was >95% in symptomatic children. The assay performed poorly in asymptomatically infected children. In agreement with previous studies in adults, the PANBIO RAD test can be useful in screening for COVID-19 in children admitted with symptoms suggestive of the disease, especially in the first days of the illness. © 2021 Wiley Periodicals LLC
- Published
- 2021
10. Pericarditis as the main clinical manifestation of covid-19 in adolescents
- Author
-
Dimopoulou, D. Spyridis, N. Dasoula, F. Krepis, P. Eleftheriou, E. Liaska, M. Servos, G. Maritsi, D. Tsolia, M.
- Abstract
Children and adolescents with severe acute respiratory syndrome coronavirus 2 infection usually have a milder illness, lower mortality rates and may manifest different clinical entities compared with adults. Acute effusive pericarditis is a rare clinical manifestation in patients with COVID-19, especially among those without concurrent pulmonary disease or myocardial injury. We present 2 cases of acute pericarditis, in the absence of initial respiratory or other symptoms, in adolescents with COVID-19. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
- Published
- 2021
11. Reducing duration of antibiotic use for presumed neonatal early-onset sepsis in greek nicus. A 'low-hanging fruit' approach
- Author
-
Kopsidas, I. Tsopela, G.-C. Molocha, N.-M. Bouza, E. Chorafa, E. Chorianopoulou, E. Giapros, V. Gkentzi, D. Gkouvas, T. Kapetanaki, A. Karachristou, K. Karavana, G. Kourkouni, E. Kourlaba, G. Lithoxopoulou, M. Papaevangelou, V. Polychronaki, M. Roilides, E. Siahanidou, T. Stratiki, E. Syrogiannopoulos, G.A. Triantafyllou, C. Tsolia, M.N. Tsouvala, E. Zaoutis, T. Spyridis, N. Preventing Hospital-Acquired Infections in Greece (PHiG) Investigators
- Abstract
Antibiotics are commonly prescribed in Neonatal Intensive Care Units (NICU), where stewardship interventions are challenging. Lowering antibiotic consumption is desperately needed in Greece, a country with high antibiotic resistance rates. We sought to assess the effectiveness of a low-cost and-resource intervention to reduce antibiotic use in Greek NICUs implementing a “low-hanging fruit” approach. A prospective quasi-experimental study was conducted in 15/17 public NICUs in Greece (9/2016–06/2019). The intervention selected was discontinuation of antibiotics within 5 days for neonates with gestational age ≥ 37 weeks, no documented signs or symptoms of sepsis, CRP ≤ 10 mg/L and negative cultures within 3 days of antibiotic initiation. Impact was evaluated by the percentage of discontinued regimens by day 5, length of therapy (LOT) and stay. Trends of antibiotic consumption were assessed with days of therapy (DOT) per 1000 patient-days. Overall, there was a 9% increase (p = 0.003) of antibiotic discontinuation in ≤5 days. In total, 7/13 (53.8%) units showed a ≥10% increase. Overall, 615 days on antibiotics per 1000 patients were saved. Interrupted time-series analysis established a declining trend in DOT/1000 patient-days relative to the pre-intervention trend (p = 0.002); a monthly decrease rate of 28.96 DOT/1000 patient-days (p = 0.001, 95%CI [−45.33, −12.60]). The intervention had no impact on antibiotic choice. Antibiotic use was successfully reduced in Greek NICUs using a “low-hanging fruit” approach. In resource-limited settings, similar targeted stewardship interventions can be applied. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- Published
- 2021
12. Eosinophilic leukaemoid reaction and myocardial involvement in a male adolescent with Toxocara canis infection
- Author
-
Krepis, P. Spyridis, N. Maritsi, D.N. Tsekoura, V. Kossiva, L.
- Published
- 2021
13. Etiology and Outcome of Candidemia in Neonates and Children in Europe: An 11-year Multinational Retrospective Study
- Author
-
Warris, A., Pana, Z.D., Oletto, A., Lundin, R., Castagnola, E., Lehrnbecher, T., Groll, A.H., Roilides, E., Andersen, C.T., Arendrup, M.C., Arsenijevic, V.A., Bianchini, S., Both, U. von, Chmelnik, M., Controzzi, T., Emonts, M., Esposito, S., Ferreras-Antolin, L., Henriet, S.S., Iosifidis, E., Irwin, A., Kopsidas, J., Lagrou, K., Lyall, H., Casteleiro, A.M., Mesini, A., Olbrich, P., Paulus, S., Lausch, K.R., Soler-Palacin, P., Spyridis, N., Strenger, V., Theodoraki, M., and Wolfs, T.
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Candida parapsilosis ,03 medical and health sciences ,[**EUROCANDY study group] ,0302 clinical medicine ,children ,030225 pediatrics ,Internal medicine ,Epidemiology ,medicine ,030212 general & internal medicine ,Candida albicans ,Candida spp ,biology ,infants ,business.industry ,candidemia ,Postmenstrual Age ,Retrospective cohort study ,Odds ratio ,biology.organism_classification ,neonates ,Confidence interval ,Infectious Diseases ,EUROCANDY Study Group ,Pediatrics, Perinatology and Child Health ,Etiology ,business - Abstract
BACKGROUND: Data on Candida bloodstream infections in pediatric patients in Europe are limited. We performed a retrospective multicenter European study of the epidemiology and outcome of neonatal and pediatric candidemia. MATERIAL AND METHODS: All first positive blood cultures from patients ≤ 18 years of age with candidemia were registered. Patients' demographic and clinical characteristics and causative Candida species were collected and analyzed. Regression analysis was used to identify factors independently associated with mortality. RESULTS: One thousand three hundred ninety-five episodes of candidemia (57.8% male) were reported from 23 hospitals in 10 European countries. Of the 1395 episodes, 36.4% occurred in neonates (≤ 44 weeks postmenstrual age), 13.8% in infants (> 44 weeks postmenstrual age to 1 year) and 49.8% in children and adolescents. Candida albicans (52.5%) and Candida parapsilosis (28%) were the predominant species. A higher proportion of candidemia caused by C. albicans was observed among neonatal patients (60.2%) with highest rates of C. parapsilosis seen among infants (42%). Children admitted to hematology-oncology wards presented the highest rates of non-albicans Candida species. Candidemia because of C. albicans was more frequent than non-albicans Candida in Northern versus Southern Europe (odds ratio, 2.3; 95% confidence interval, 1.8-2.9; P < 0.001). The all-cause mortality at 30 days was 14.4%. All-cause mortality was higher among patients admitted to the neonatal or pediatric intensive care units than other wards. Over time, no significant changes in species distribution were observed. CONCLUSIONS: This first multicenter European study shows unique characteristics of the epidemiology of pediatric candidemia. The insights obtained from this study will be useful to guide clinical management and antifungal stewardship. ispartof: Pediatr Infect Dis J vol:39 issue:2 pages:114-120 ispartof: location:United States status: published
- Published
- 2020
- Full Text
- View/download PDF
14. A survey on national pediatric antibiotic stewardship programs, networks and guidelines in 23 European countries
- Author
-
Kopsidas, I. Vergnano, S. Spyridis, N. Zaoutis, T. Patel, S.
- Abstract
Background: Misuse, overuse of antimicrobials and increasing rates of antimicrobial resistance are well-recognized problems throughout Europe. The aim of this survey was to describe the current pediatric antibiotic stewardship (PAS) landscape across Europe and identify gaps, in terms of national programs, networks and guidelines. Methods: A survey of 17 questions was circulated in July 2019 among 24 European pediatric infectious disease researchers and clinicians, professors and heads of department on the existence of PAS programs, national networks and meetings, established competencies, metrics and guidelines. Results: We received responses from 23 countries. National guidelines on the management of children with common infections treated in hospital settings exist in 15 of 23 (70%); only 8 of 15 (53%) had been updated within the previous 4 years. Most provide guidance on antibiotic initiation and duration (14 of 15, 93%), but few on when to transition from intravenous to oral antibiotics (7 of 15, 47%). National PAS competencies have only been developed in 4 countries; only 1 addressed both community and hospital prescribing. Organized national PAS networks are only established in the United Kingdom and Germany; 21 of 23, 91% countries had no agreed metric for antibiotic prescribing in children; 2 of 23 were based on daily defined doses. Conclusions: Fragmented implementation of PAS programs, no agreed metrics, lack of established PAS competencies and national PAS networks along with inexistent funding is alarming in view of existing high rates of antimicrobial resistance in Europe. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
- Published
- 2020
15. Epidemiology of infections and antimicrobial use in Greek Neonatal Units
- Author
-
Gkentzi, D, Kortsalioudaki, C, Cailes, BC, Zaoutis, T, Kopsidas, J, Tsolia, M, Spyridis, N, Siahanidou, S, Sarafidis, K, Heath, PT, Dimitriou, G, and Neonatal Infection Surveillance Network in Greece
- Abstract
OBJECTIVE: To describe the epidemiology of neonatal infections and of antimicrobial use in Greek Neonatal Units (NNUs) in order to develop national, evidence-based guidelines on empiric antimicrobial use for neonatal sepsis in Greece. DESIGN: Retrospective analysis of prospectively collected infection surveillance data from 2012 to 2015, together with a Point Prevalence Survey (PPS) on antimicrobial use and the collection of data on local empiric antimicrobial policies. SETTING: 16 NNUs in Greece participating in the neonIN infection surveillance network PATIENTS: Newborns in participating NNUs who had a positive blood, cerebrospinal fluid or urine culture and were treated with at least 5 days of antibiotics. RESULTS: 459 episodes were recorded in 418 infants. The overall incidence of infection was 50/1000 NNU-admissions. The majority of episodes were late-onset sepsis (LOS) (413, 90%). Coagulase-negative Staphylococci (80%) were the most common Gram-positive organisms causing LOS and Klebsiella spp (39%) the most common Gram-negative. Nearly half (45%) of the Klebsiella spp were resistant to at least one aminoglycoside. The PPS revealed that 196 of 484 (40%) neonates were on antimicrobials. The survey revealed wide variation in empiric antimicrobial policies for LOS. CONCLUSIONS: This is the largest collection of data on the epidemiology of neonatal infections in Greece and on neonatal antimicrobial use. It provides the background for the development of national evidence-based guidelines. Continuous surveillance, the introduction of antimicrobial stewardship interventions and evidence-based guidelines are urgently required.
- Published
- 2019
16. The worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children
- Author
-
Versporten A1, Bielicki J2, Drapier N1, Sharland M2, Goossens H3, ARPEC project group. Calle GM, Garrahan JP, Clark J, Cooper C, Blyth CC, Francis JR, Alsalman J, Jansens H, Mahieu L, Van Rossom P, Vandewal W, Lepage P, Blumental S, Briquet C, Robbrecht D, Maton P, Gabriels P, Rubic Z, Kovacevic T, Nielsen JP, Petersen JR, Poorisrisak P, Jensen LH, Laan M, Tamm E, Matsinen M, Rummukainen ML, Gajdos V, Olivier R, Le Maréchal F, Martinot A, Dubos F, Lagrée M, Prot-Labarthe S, Lorrot M, Orbach D, Pagava K, Hufnagel M, Knuf M, Schlag SA, Liese J, Renner L, Enimil A, Awunyo M, Syridou G, Spyridis N, Critselis E, Kouni S, Mougkou K, Ladomenou F, Gkentzi D, Iosifidis E, Roilides E, Sahu S, Murki S, Malviya M, Kalavalapalli DB, Singh S, Singhal T, Garg G, Garg P, Kler N, Soltani J, Jafarpour Z, Pouladfar G, Nicolini G, Montagnani C, Galli L, Esposito S, Tenconi R, Lo Vecchio A, Dona' D, Giaquinto C, Borgia E, D'Argenio P, De Luca M, Centenari C, Raka L, Raka D, Omar A, Al-Mousa H, Mozgis D, Sviestina I, Burokiene S, Usonis V, Tavchioska G, Hargadon-Lowe A, Zarb P, Borg MA, González Lozano CA, Zárate Castañon P, Cancino ME, McCullagh B, McCorry A, Gormley C, Al Maskari Z, Al-Jardani A, Pluta M, Rodrigues F, Brett A, Esteves I, Marques L, Ali AlAjmi J, Claudia Cambrea S, Rashed AN, Mubarak Al Azmi AA, Chan SM, Isa MS, Najdenov P, Čižman M, Unuk S, Finlayson H, Dramowski A, Maté-Cano I, Soto B, Calvo C, Santiago B, Saavedra-Lozano J, Bustinza A, Escosa-García L, Ureta N, Lopez-Varela E, Rojo P, Tagarro A, Barrero PT, Rincon-Lopez EM, Abubakar I, Aston J, Heginbothom M, Satodia P, Garbash M, Johnson A, Sharpe D, Barton C, Menson E, Arenas-Lopez S, Luck S, Doerholt K, McMaster P, Caldwell NA, Lunn A, Drysdale SB, Howe R, Scorrer T, Gahleitner F, Gupta R, Nash C, Alexander J, Raman M, Bell E, Rajagopal V, Kohlhoff S, Cox E, Zaoutis T., Mahieu, Ludo, ARPEC Project Grp, ARPEC project group, Versporten, A1, Bielicki, J2, Drapier, N1, Sharland, M2, Goossens, H3, ARPEC project group., Calle GM, Garrahan, Jp, Clark, J, Cooper, C, Blyth, Cc, Francis, Jr, Alsalman, J, Jansens, H, Mahieu, L, Van Rossom, P, Vandewal, W, Lepage, P, Blumental, S, Briquet, C, Robbrecht, D, Maton, P, Gabriels, P, Rubic, Z, Kovacevic, T, Nielsen, Jp, Petersen, Jr, Poorisrisak, P, Jensen, Lh, Laan, M, Tamm, E, Matsinen, M, Rummukainen, Ml, Gajdos, V, Olivier, R, Le Maréchal, F, Martinot, A, Dubos, F, Lagrée, M, Prot-Labarthe, S, Lorrot, M, Orbach, D, Pagava, K, Hufnagel, M, Knuf, M, Schlag, Sa, Liese, J, Renner, L, Enimil, A, Awunyo, M, Syridou, G, Spyridis, N, Critselis, E, Kouni, S, Mougkou, K, Ladomenou, F, Gkentzi, D, Iosifidis, E, Roilides, E, Sahu, S, Murki, S, Malviya, M, Kalavalapalli, Db, Singh, S, Singhal, T, Garg, G, Garg, P, Kler, N, Soltani, J, Jafarpour, Z, Pouladfar, G, Nicolini, G, Montagnani, C, Galli, L, Esposito, S, Tenconi, R, Lo Vecchio, A, Dona', D, Giaquinto, C, Borgia, E, D'Argenio, P, De Luca, M, Centenari, C, Raka, L, Raka, D, Omar, A, Al-Mousa, H, Mozgis, D, Sviestina, I, Burokiene, S, Usonis, V, Tavchioska, G, Hargadon-Lowe, A, Zarb, P, Borg, Ma, González Lozano, Ca, Zárate Castañon, P, Cancino, Me, Mccullagh, B, Mccorry, A, Gormley, C, Al Maskari, Z, Al-Jardani, A, Pluta, M, Rodrigues, F, Brett, A, Esteves, I, Marques, L, Ali AlAjmi, J, Claudia Cambrea, S, Rashed, An, Mubarak Al Azmi, Aa, Chan, Sm, Isa, M, Najdenov, P, Čižman, M, Unuk, S, Finlayson, H, Dramowski, A, Maté-Cano, I, Soto, B, Calvo, C, Santiago, B, Saavedra-Lozano, J, Bustinza, A, Escosa-García, L, Ureta, N, Lopez-Varela, E, Rojo, P, Tagarro, A, Barrero, Pt, Rincon-Lopez, Em, Abubakar, I, Aston, J, Heginbothom, M, Satodia, P, Garbash, M, Johnson, A, Sharpe, D, Barton, C, Menson, E, Arenas-Lopez, S, Luck, S, Doerholt, K, Mcmaster, P, Caldwell, Na, Lunn, A, Drysdale, Sb, Howe, R, Scorrer, T, Gahleitner, F, Gupta, R, Nash, C, Alexander, J, Raman, M, Bell, E, Rajagopal, V, Kohlhoff, S, Cox, E, and Zaoutis, T.
- Subjects
0301 basic medicine ,Male ,Pediatrics ,Latin Americans ,Cross-sectional study ,Prevalence ,Psychological intervention ,Drug resistance ,Global Health ,infectious diseases ,0302 clinical medicine ,Global health ,Medicine ,030212 general & internal medicine ,Child ,antibiotics, children ,Drugs -- Prescribing ,Pharmacology. Therapy ,Hospitals -- Europe ,Drug Resistance, Microbial ,Hospitals ,Anti-Bacterial Agents ,Europe ,Child, Preschool ,Anti-infective agents ,Female ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,Cefepime ,030106 microbiology ,Drug Prescriptions ,03 medical and health sciences ,Surgical prophylaxis ,pharmacology ,pharmacology (medical) ,Environmental health ,Humans ,Biology ,Quality Indicators, Health Care ,business.industry ,Health status indicators -- Europe ,Infant ,Drug Utilization ,Cross-Sectional Studies ,Health Care Surveys ,Human medicine ,business - Abstract
Objectives: Previously, web-based tools for cross-sectional antimicrobial point prevalence surveys (PPSs) have been used in adults to develop indicators of quality improvement. We aimed to determine the feasibility of developing similar quality indicators of improved antimicrobial prescribing focusing specifically on hospitalized neonates and children worldwide. Methods: A standardized antimicrobial PPS method was employed. Included were all inpatient children and neonates receiving an antimicrobial at 8:00 am on the day of the PPS. Denominators included the total number of inpatients. A web-based application was used for data entry, validation and reporting. We analysed 2012 data from 226 hospitals (H) in 41 countries (C) from Europe (174H; 24C), Africa (6H; 4C), Asia (25H; 8C), Australia (6H), Latin America (11H; 3C) and North America (4H). Results: Of 17693 admissions, 6499 (36.7%) inpatients received at least one antimicrobial, but this varied considerably between wards and regions. Potential indicators included very high broad-spectrum antibiotic prescribing in children of mainly ceftriaxone (ranked first in Eastern Europe, 31.3%; Asia, 13.0%; Southern Europe, 9.8%), cefepime (ranked third in North America, 7.8%) and meropenem (ranked first in Latin America, 13.1%). The survey identified worryingly high use of critically important antibiotics for hospital-acquired infections in neonates (34.9%; range from 14.2% in Africa to 68.0% in Latin America) compared with children (28.3%; range from 14.5% in Africa to 48.9% in Latin America). Parenteral administration was very common among children in Asia (88%), Latin America (81%) and Europe (67%). Documentation of the reasons for antibiotic prescribing was lowest in Latin America (52%). Prolonged surgical prophylaxis rates ranged from 78% (Europe) to 84% (Latin America). Conclusions: Simple web-based PPS tools provide a feasible method to identify areas for improvement of antibiotic use, to set benchmarks and to monitor future interventions in hospitalized neonates and children. To our knowledge, this study has derived the first global quality indicators for antibiotic use in hospitalized neonates and children., peer-reviewed
- Published
- 2018
17. Decreased antibodies against rubella in previously vaccinated treatment-naïve childhood systemic lupus erythematous patients: a prospective case–control study
- Author
-
Maritsi, D.N. Coffin, S. Onoufriou, M. Spyridis, N. Tsolia, M.N.
- Published
- 2019
18. Risk Factors Associated With Accelerated Rubella IgG Antibody Loss in Previously Vaccinated, Treatment-Naive Patients With Juvenile Systemic Lupus Erythematosus: A Prospective Study
- Author
-
Maritsi, D.N. Eleftheriou, I. Vartzelis, G. Spyridis, N. Tsolia, M.N.
- Published
- 2019
19. The Jumping Up (J-Up) Test: Making the Diagnosis of Acute Appendicitis Easier in Children
- Author
-
Tzortzopoulou, A.K. Giamarelou, P. Tsolia, M. Spyridis, N. Vakaki, M. Passalides, A. Zavras, N.
- Abstract
We evaluate a new clinical test, jumping up (J-up) test, to diagnose easier appendicitis in children. A total of 407 patients, aged 5 to16 years, with right lower quadrant abdominal pain were asked to jump rising both hands and trying to reach a toy hanging down from the ceiling of the examination room. Bieri pediatric Face Pain Scale was used for recording the pain response. J-up test has sensitivity of 87% and specificity of 70%. A positive J-up test combined with leukocytosis (white blood cells count >12 000/mm3), neutrophilia >75%, neutrophil/lymphocyte >2, and C-reactive protein >5 mg/dL, achieved a posttest probability of appendicitis of 85%. A negative J-up test combined with the aforementioned blood markers within normal range had a posttest probability for non-appendicitis of 92%. J-up test is a reliable clinical test, which could be used even by an inexperienced doctor. Combined with classical blood markers, it could successfully predict which child is in urgent need or not of surgery. © The Author(s) 2019.
- Published
- 2019
20. Establishing nationally representative central line-associated bloodstream infection surveillance data for paediatric patients in Greece
- Author
-
Kouni, S. Tsolia, M. Roilides, E. Dimitriou, G. Tsiodras, S. Skoutelis, A. Kourkouni, E. Gkentzi, D. Iosifidis, E. Spyridis, N. Kopsidas, I. Karakosta, P. Tsopela, G.C. Spyridaki, I. Kourlaba, G. Coffin, S. Zaoutis, E.T. Papaevangelou, V. Triantafyllidou, P. Fanaraki, E. Kaisari, K. Kalabalikis, P. Karachristou, K. Katsibardi, K. Kattamis, A. Kazantzi, M. Kitra, V. Lourida, A. Mpouza, E. Papadopoulou, S. Petrikkos, L. Polychronopoulou, S. Siahanidou, T. Zannikos, K. Giannopoulos, A. Hatzipantelis, E. Tragiannidis, A. Goumperi, S. Sdougka, M. Lithoxopoulou, M. Soubasi, V. Baka, M. Dimolitsa, C. Doganis, D. Kapetanakis, I. Mavrogeorgos, G. Nika, A. Papachristidou, S. Papadatos, I. Tsintoni, A. Baroutis, G. Stratiki, E. Skordala-Riti, M. Tsouvala, E. Gaitana, C. Grivea, I. Kaffe, A. Giapros, V. Gouvias, T. Drougia, A. Theodoraki, M. Karavana, G. Koropouli, M. Thomou, C. Kapetanaki, A. Tzaki, M. Maistreli, S. the PHIG Investigators
- Abstract
Background: Healthcare-associated infections (HCAIs) are associated with increased morbidity and mortality and with excess costs. Central line-associated bloodstream infections (CLABSIs) are the most common HCAIs in neonates and children. Aim: To establish national benchmark data for rates of CLABSI in neonatal and paediatric intensive care units (NICUs and PICUs) and paediatric oncology units (ONCs). Methods: Active surveillance for CLABSI was conducted from June 2016 to February 2017. A collaborative of 14 NICUs, four PICUs, and six ONCs participated in the programme. Surveillance definitions of central line (CL), central line utilization (CLU) ratio, CLABSI event, and CLABSI rate were based on the Centers for Disease Control and Prevention's 2014 National Healthcare Safety Network criteria. Medical records were assessed daily for calculating CL-days, patient-days, and susceptibility of isolated organisms. Findings: A total of 111 CLABSI episodes were recorded. The overall mean CLABSI rate was 4.41 infections per 1000 CL-days, and the CLU ratio was 0.31. CLABSI rates were 6.02 in NICUs, 6.09 in PICUs, and 2.78 per 1000 CL-days in ONCs. A total of 123 pathogens were isolated. The most common pathogens were Enterobacteriaceae (36%), followed by Gram-positive cocci (29%), non-fermenting Gram-negative bacteria (16%), and fungi (16%). Overall, 37% of Gram-negative pathogens were resistant to third-generation cephalosporins and 37% to carbapenems. Conclusion: Nationally representative CLABSI rates were determined for paediatric patients. These data could be used to benchmark and serve as baseline data for the design and evaluation of infection control and antimicrobial stewardship interventions. © 2018 The Healthcare Infection Society
- Published
- 2019
21. Epidemiology of infections and antimicrobial use in Greek Neonatal Units
- Author
-
Gkentzi, D. Kortsalioudaki, C. Cailes, B.C. Zaoutis, T. Kopsidas, J. Tsolia, M. Spyridis, N. Siahanidou, S. Sarafidis, K. Heath, P.T. Dimitriou, G.
- Abstract
Objective To describe the epidemiology of neonatal infections and of antimicrobial use in Greek Neonatal Units (NNUs) in order to develop national, evidence-based guidelines on empiric antimicrobial use for neonatal sepsis in Greece. Design Retrospective analysis of prospectively collected infection surveillance data from 2012 to 2015, together with a Point Prevalence Survey (PPS) on antimicrobial use and the collection of data on local empiric antimicrobial policies. Setting 16 NNUs in Greece participating in the neonIN infection surveillance network Patients Newborns in participating NNUs who had a positive blood, cerebrospinal fluid or urine culture and were treated with at least 5 days of antibiotics. Results 459 episodes were recorded in 418 infants. The overall incidence of infection was 50/1000 NNU-admissions. The majority of episodes were late-onset sepsis (LOS) (413, 90%). Coagulase-negative Staphylococci (80%) were the most common Gram-positive organisms causing LOS and Klebsiella spp (39%) the most common Gram-negative. Nearly half (45%) of the Klebsiella spp were resistant to at least one aminoglycoside. The PPS revealed that 196 of 484 (40%) neonates were on antimicrobials. The survey revealed wide variation in empiric antimicrobial policies for LOS. Conclusions This is the largest collection of data on the epidemiology of neonatal infections in Greece and on neonatal antimicrobial use. It provides the background for the development of national evidence-based guidelines. Continuous surveillance, the introduction of antimicrobial stewardship interventions and evidence-based guidelines are urgently required. © 2019 Author(s) (or their employer(s)). Re-use permitted under CC BY-NC.
- Published
- 2019
22. Long-term preservation of measles and rubella specific-IgG antibodies in children with enthesitis related arthritis on anti-TNFα treatment: A prospective controlled study
- Author
-
Maritsi, D.N. Kopsidas, I. Vartzelis, G. Spyridis, N. Tsolia, M.N.
- Published
- 2019
23. PB2323 CORRELATION BETWEEN COLONIZATION AND BACTERAEMIA FROM MULTIDRUG RESISTANT SPECIES IN PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION
- Author
-
Liga, M., primary, Aggelinas, D., additional, Spyridis, N., additional, Lekka, K., additional, Korovila, C., additional, Paliogianni, F., additional, Marangos, M., additional, and Spyridonidis, A., additional
- Published
- 2019
- Full Text
- View/download PDF
24. Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data
- Author
-
Bielicki, J. A., Sharland, M., Johnson, A. P., Henderson, K. L., Cromwell, D. A., Berger, C., Esposito, Susanna Maria Roberta, Danieli, E., Tenconi, R., Folgori, L., Bernaschi, P., Santiago, B., Saavedra, J., Cercenado, E., Brett, A., Rodrigues, F., Cizman, M., Jazbec, J., Babnik, J., Pavčnik, M., Pirš, M., Mueller Premrov, M., Lindner, M., Borte, M., Lippmann, N., Schuster, V., Thürmer, A., Lander, F., Elias, J., Liese, J., Durst, A., Weichert, S., Schneider, C., Hufnagel, M., Rack, A., Hübner, J., Dubos, F., Lagree, M., Dessein, R., Tissieres, P., Cuzon, G., Gajdos, V., Doucet Populaire, F., Usonis, V., Gurksniene, V., Bernatoniene, G., Tsolia, M., Spyridis, N., Lebessi, E., Doudoulakakis, A., Lutsar, I., Kõljalg, S., Schülin, T., and Warris, A.
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,030106 microbiology ,MEDLINE ,Bacteremia ,Microbial Sensitivity Tests ,Drug resistance ,Decision Support Techniques ,03 medical and health sciences ,Bayes' theorem ,pharmacology ,pharmacology (medical) ,infectious diseases ,0302 clinical medicine ,Antibiotic resistance ,030225 pediatrics ,Humans ,Medicine ,Pharmacology (medical) ,Medical prescription ,Child ,Intensive care medicine ,Pharmacology ,Bacteria ,business.industry ,Incidence ,Incidence (epidemiology) ,Infant, Newborn ,Infant ,Bayes Theorem ,medicine.disease ,Anti-Bacterial Agents ,Regimen ,Infectious Diseases ,Child, Preschool ,Epidemiological Monitoring ,Emergency medicine ,Female ,business - Abstract
OBJECTIVES: The objective of this study was to evaluate the ability of weighted-incidence syndromic combination antibiograms (WISCAs) to inform the selection of empirical antibiotic regimens for suspected paediatric bloodstream infections (BSIs) by comparing WISCAs derived using data from single hospitals and from a multicentre surveillance dataset. METHODS: WISCAs were developed by estimating the coverage of five empirical antibiotic regimens for childhood BSI using a Bayesian decision tree. The study used microbiological data on ∼2000 bloodstream isolates collected over 2 years from 19 European hospitals. We evaluated the ability of a WISCA to show differences in regimen coverage at two exemplar hospitals. For each, a WISCA was first calculated using only their local data; a second WISCA was calculated using pooled data from all 19 hospitals. RESULTS: The estimated coverage of the five regimens was 72%-86% for Hospital 1 and 79%-94% for Hospital 2, based on their own data. In both cases, the best regimens could not be definitively identified because the differences in coverage were not statistically significant. For Hospital 1, coverage estimates derived using pooled data gave sufficient precision to reveal clinically important differences among regimens, including high coverage provided by a narrow-spectrum antibiotic combination. For Hospital 2, the hospital and pooled data showed signs of heterogeneity and the use of pooled data was judged not to be appropriate. CONCLUSIONS: The Bayesian WISCA provides a useful approach to pooling information from different sources to guide empirical therapy and could increase confidence in the selection of narrow-spectrum regimens.
- Published
- 2015
- Full Text
- View/download PDF
25. Variation in paediatric hospital antibiotic guidelines in Europe
- Author
-
Spyridis, N., Syridou, G., Goossens, H., Versporten, A., Kopsidas, J., Kourlaba, G., Bielicki, J., Drapier, N., Zaoutis, T., Tsolia, M., Sharland, M., Vergison, A., Leon, V., Delestrait, M., Huza, C., Lepage, P., Mahieu, L., Boy, T., Jansens, H., Van Der Linden, D., Briquet, C., Allegaert, K., Smits, A., Gabriels, P., Vuye, A., Lutsar, I., Tamm, E., Larionova, A., Laan, D., Orbach, M., Lorrot, M., Angoulvant, F., Prot-Labarthe, S., Dubos, F., Lagree, M., Hufnagel, M., Schuster, K., Henneke, P., Roilides, E., Iosifidis, E., Corovessi, V., Michos, A., Galanakis, E., Gkentzi, D., Giacquinto, C., Longo, G., Dona', D., Mion, T., D'Argenio, P., Degli, M. L. C., De Luca, M., Ciliento, G., Esposito, S., Danieli, E., Montinaro, V., Tenconi, R., Nicolini, G., Sviestina, C. I. M., Pavare, J., Rasnaca, K., Gardovska, D., Usonis, V., Grope, I., Gurksniene, V., Eidukaite, A., Biver, A., Brett, A., Esteves, I., Cambrea, S. C., Craiu, M., Tomescu, E., Cizman, M., Babnik, J., Kenda, R., Vidmar, I., Nunez-Cuadros, E., Rojo, P., Lopez-Varela, E., Ureta, N., Perez-Lopez, A., Mosqueda, R., Orta, L., Santos, M., Navarro, M., Santiago, B., Hernandez-Sampelaya, T., Saavedra, J., Pineiro, R., Torel, P., Cano, I. M., Baumann, P., Berger, C., Menson, E., Botgros, A., Doerholt, K., Drysdale, S., Makwana, N., Mccorry, A., Garbash, E. M., Chetcutiganado, C., Mcleod, M., Caldwell, N., Nash, C., Mccullagh, B., Sharpe, D., Tweddell, L., Liese, J. G., Aston, J., Gallagher, A., Satodia, P., Howard-Smith, N., Korinteli, I., Tavchioska, G., Jensen, L., Trethon, A., Unuk, S., Childs, N., Canlas, J., Mahieu, Ludo, and ARPEC Project Grp
- Subjects
Pediatrics ,practice guidelines as topic ,Antibiotics ,cross-sectional studies ,respiratory tract infections ,sepsis ,0302 clinical medicine ,newborn ,Medicine ,030212 general & internal medicine ,Practice Patterns, Physicians' ,humans ,European paediatric hospitals ,antibiotic guidelines ,childhood infection ,anti-bacterial agents ,bacterial infections ,child ,preschool ,drug administration schedule ,drug prescriptions ,Europe ,hospitals ,pediatric ,infant ,practice patterns ,physicians' ,urinary tract infections ,pediatrics ,perinatology and child health ,Antistaphylococcal penicillins ,Respiratory tract infections ,Neonatal sepsis ,Hospitals, Pediatric ,Child, Preschool ,medicine.drug ,medicine.medical_specialty ,medicine.drug_class ,Sepsis ,03 medical and health sciences ,030225 pediatrics ,Internal medicine ,business.industry ,Infant, Newborn ,Guideline ,Amoxicillin ,medicine.disease ,Penicillin ,Pediatrics, Perinatology and Child Health ,Human medicine ,business - Abstract
ObjectiveTo assess the availability and source of guidelines for common infections in European paediatric hospitals and determine their content and characteristics.DesignParticipating hospitals completed an online questionnaire on the availability and characteristics of antibiotic prescribing guidelines and on empirical antibiotic treatment including duration of therapy for 5 common infection syndromes: respiratory tract, urinary tract, skin and soft tissue, osteoarticular and sepsis in neonates and children.Results84 hospitals from 19 European countries participated in the survey of which 74 confirmed the existence of guidelines. Complete guidelines (existing guidelines for all requested infection syndromes) were reported by 20% of hospitals and the majority (71%) used a range of different sources. Guidelines most commonly available were those for urinary tract infection (UTI) (74%), neonatal sepsis (71%) and sepsis in children (65%). Penicillin and amoxicillin were the antibiotics most commonly recommended for respiratory tract infections (RTIs) (up to 76%), cephalosporin for UTI (up to 50%) and for skin and soft tissue infection (SSTI) and bone infection (20% and 30%, respectively). Antistaphylococcal penicillins were recommended for SSTIs and bone infections in 43% and 36%, respectively. Recommendations for neonatal sepsis included 20 different antibiotic combinations. Duration of therapy guidelines was mostly available for RTI and UTI (82%). A third of hospitals with guidelines for sepsis provided recommendations for length of therapy.ConclusionsComprehensive antibiotic guideline recommendations are generally lacking from European paediatric hospitals. We documented multiple antibiotics and combinations for most infections. Considerable improvement in the quality of guidelines and their evidence base is required, linking empirical therapy to resistance rates.
- Published
- 2015
- Full Text
- View/download PDF
26. An 11-Year-Old Male with Vertebral Osteomyelitis and a Paraspinal Abscess
- Author
-
Kopsidas, I. Margariti, R. Gavra, M. Syngelou, A. Zambakidis, C. Tsolia, M. Nikolaidis, N. Spyridis, N.
- Subjects
bacterial infections and mycoses - Abstract
We report the case of an 11-year-old immunocompetent patient presenting with a 2-week history of upper back pain, diagnosed with thoracic vertebral osteomyelitis and a paraspinal abscess caused by Bartonella henselae. He was treated with gentamicin and doxycycline followed by oral rifampicin and doxycycline with favorable outcome. © 2019 Wolters Kluwer Health, Inc. All rights reserved.
- Published
- 2018
27. Antibody status against measles in previously vaccinated childhood systemic lupus erythematosus patients: A prospective case-control study
- Author
-
Maritsi, D.N. Vartzelis, G. Kopsidas, J. Spyridis, N. Tsolia, M.N.
- Published
- 2018
28. Establishing nationally representative central line-associated bloodstream infection surveillance data for paediatric patients in Greece
- Author
-
Kouni, S., primary, Tsolia, M., additional, Roilides, E., additional, Dimitriou, G., additional, Tsiodras, S., additional, Skoutelis, A., additional, Kourkouni, E., additional, Gkentzi, D., additional, Iosifidis, E., additional, Spyridis, N., additional, Kopsidas, I., additional, Karakosta, P., additional, Tsopela, G.C., additional, Spyridaki, I., additional, Kourlaba, G., additional, Coffin, S., additional, Zaoutis, E.T., additional, Papaevangelou, V., additional, Triantafyllidou, P., additional, Fanaraki, E., additional, Kaisari, K., additional, Kalabalikis, P., additional, Karachristou, K., additional, Katsibardi, K., additional, Kattamis, A., additional, Kazantzi, M., additional, Kitra, V., additional, Lourida, A., additional, Mpouza, E., additional, Papadopoulou, S., additional, Petrikkos, L., additional, Polychronopoulou, S., additional, Siahanidou, T., additional, Zannikos, K., additional, Giannopoulos, A., additional, Hatzipantelis, E., additional, Tragiannidis, A., additional, Goumperi, S., additional, Sdougka, M., additional, Lithoxopoulou, M., additional, Soubasi, V., additional, Baka, M., additional, Dimolitsa, C., additional, Doganis, D., additional, Kapetanakis, I., additional, Mavrogeorgos, G., additional, Nika, A., additional, Papachristidou, S., additional, Papadatos, I., additional, Tsintoni, A., additional, Baroutis, G., additional, Stratiki, E., additional, Skordala-Riti, M., additional, Tsouvala, E., additional, Gaitana, C., additional, Grivea, I., additional, Kaffe, A., additional, Giapros, V., additional, Gouvias, T., additional, Drougia, A., additional, Theodoraki, M., additional, Karavana, G., additional, Koropouli, M., additional, Thomou, C., additional, Kapetanaki, A., additional, Tzaki, M., additional, and Maistreli, S., additional
- Published
- 2019
- Full Text
- View/download PDF
29. Decreased antibodies against rubella in previously vaccinated treatment-naïve childhood systemic lupus erythematous patients: a prospective case–control study
- Author
-
Maritsi, DN, primary, Coffin, S, additional, Onoufriou, M, additional, Spyridis, N, additional, and Tsolia, MN, additional
- Published
- 2018
- Full Text
- View/download PDF
30. Emergence of a staphylococcus aureus clone resistant to mupirocin and fusidic acid carrying exotoxin genes and causing mainly skin infections
- Author
-
Doudoulakakis, A. Spiliopoulou, I. Spyridis, N. Giormezis, N. Kopsidas, J. Militsopoulou, M. Lebessi, E. Tsolia, M.
- Subjects
bacterial infections and mycoses - Abstract
Skin and soft tissue infections (SSTIs) caused by mupirocin-resistant Staphylococcus aureus strains have recently increased in number in our settings. We sought to evaluate the characteristics of these cases over a 43-month period. Data for all community-acquired staphylococcal infections caused by mupirocin-resistant strains were retrospectively reviewed. Genes encoding products producing high-level resistance (HLR) to mupirocin (mupA), fusidic acid resistance (fusB), resistance to macrolides and lincosamides (ermC and ermA), Panton-Valentine leukocidin (PVL) (lukS/lukF-PV), exfoliative toxins (eta and etb), and fibronectin binding protein A (fnbA) were investigated by PCRs in 102 selected preserved strains. Genotyping was performed by SCCmec and agr typing, whereas clonality was determined by pulsedfield gel electrophoresis (PFGE) and multilocus sequence typing (MLST). A total of 437 cases among 2,137 staphylococcal infections were recorded in 2013 to 2016; they were all SSTIs with the exception of 1 case of primary bacteremia. Impetigo was the predominant clinical entity (371 cases [84.9%]), followed by staphylococcal scalded skin syndrome (21 cases [4.8%]), and there were no abscesses. The number of infections detected annually increased during the study years. All except 3 isolates were methicillin susceptible. The rates of HLR to mupirocin and constitutive resistance to clindamycin were 99% and 20.1%, respectively. Among the 102 tested strains, 100 (98%) were mupA positive and 97 (95%) were fusB positive, 26/27 clindamycin-resistant strains (96.3%) were ermA positive, 83 strains (81.4%) were lukS/lukF positive, 95 (93%) carried both eta and etb genes, and 99 (97%) were fnbA positive. Genotyping of methicillin-sensitive S. aureus (MSSA) strains revealed that 96/99 (96.7%) belonged to one main pulsotype, pulsotype 1, classified as sequence type 121 (ST121). The emergence of a single MSSA clone (ST121) causing impetigo was documented. Resistance to topical antimicrobials and a rich toxinogenic profile confer to this clone adaptability for spread in the community.
- Published
- 2017
31. Short-course Regimens of Liposomal Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis in Children: An 11-year Retrospective Study at a Tertiary Care Center
- Author
-
Krepis, P. Argyri, I. Krepi, A. Syrmou, A. Spyridis, N. Tsolia, M.
- Abstract
Background: Visceral leishmaniasis (VL) remains an important public health problem in endemic regions. Current antileishmanial agents share several limitations including potentially serious side effects and the risk of clinical failure. Objectives: Aim of this study was to examine the effectiveness and safety of short-course liposomal amphotericin B (L-AmB) regimens in the treatment of childhood VL in our area. Methods: The cases of 43 VL patients (20 males; 23 females; mean age: 4.6 years) treated at a tertiary children's hospital over an 11-year period were retrospectively reviewed. Diagnosis was confirmed with identification of Leishmania spp. in bone marrow samples and/or a positive serologic test. All patients were treated with 5 different L-AmB regimens at a dose of 18-22 mg/kg. Results: Initial response to treatment was attained in all patients (100%), while definitive cure at 6 months was achieved in 98% of patients. Adverse effects were recorded in 14 children and consisted mostly of infusion reactions and electrolyte disorders. Self-limiting nephrotoxicity was observed in 3 patients including a 12-year-old girl in whom acute kidney injury was developed. In addition, ventricular arrhythmias developed in a 13-year-old boy necessitating drug discontinuation. Although side effects were more frequent with the 2-day regimen, the difference with regard to toxicity between dosing regimens was not significant. Conclusions: Short-course L-AmB regimens are effective and safe for the treatment of childhood VL in our area. Our findings suggest that large L-AmB doses can possibly account for a higher rate of adverse events including nephrotoxicity. © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
- Published
- 2017
32. The worldwide antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey: Developing hospital-quality indicators of antibiotic prescribing for children
- Author
-
Versporten, A. Bielicki, J. Drapier, N. Sharland, M. Goossens, H. Calle, G.M. Clark, J. Cooper, C. Blyth, C.C. Francis, J.R. Alsalman, J. Jansens, H. Mahieu, L. Van Rossom, P. Vandewal, W. Lepage, P. Blumental, S. Briquet, C. Robbrecht, D. Maton, P. Gabriels, P. Rubic, Z. Kovacevic, T. Nielsen, J.P. Petersen, J.R. Poorisrisak, P. Jensen, L.H. Laan, M. Tamm, E. Matsinen, M. Rummukainen, M.-L. Gajdos, V. Olivier, R. Le Maréchal, F. Martinot, A. Prot-Labarthe, S. Lorrot, M. Orbach, D. Pagava, K. Hufnagel, M. Knuf, M. Schlag, S.A.A. Liese, J. Renner, L. Enimil, A. Awunyo, M. Syridou, G. Spyridis, N. Critselis, E. Kouni, S. Mougkou, K. Ladomenou, F. Gkentzi, D. Iosifidis, E. Roilides, E. Sahu, S. Murki, S. Malviya, M. Kalavalapalli, D.B. Singh, S. Singhal, T. Garg, G. Garg, P. Kler, N. Soltani, J. Jafarpour, Z. Pouladfar, G. Nicolini, G. Montagnani, C. Galli, L. Esposito, S. Vecchio, A.L. Dona', D. Giaquinto, C. Borgia, E. D'Argenio, P. De Luca, M. Centenari, C. Raka, L. Omar, A. Al-Mousa, H. Mozgis, D. Sviestina, I. Burokiene, S. Usonis, V. Tavchioska, G. Hargadon-Lowe, A. Zarb, P. Borg, M.A. González Lozano, C.A. Castañon, P.Z. Cancino, M.E. McCullagh, B. McCorry, A. Gormley, C. Al Maskari, Z. Al-Jardani, A. Pluta, M. Rodrigues, F. Brett, A. Esteves, I. Marques, L. AlAjmi, J.A. Cambrea, S.C. Rashed, A.N. Al Azmi, A.A.M. Chan, S.M. Isa, M.S. Najdenov, P. Čižman, M. Unuk, S. Finlayson, H. Dramowski, A. Maté-Cano, I. Soto, B. Calvo, C. Santiago, B. Saavedra-Lozano, J. Bustinza, A. Escosa-García, L. Ureta, N. Tagarro, A. Barrero, P.T. Rincon-Lopez, E.M. Abubakar, I. Aston, J. Heginbothom, M. Satodia, P. Garbash, M. Johnson, A. Sharpe, D. Barton, C. Menson, E. Arenas-Lopez, S. Luck, S. Doerholt, K. McMaster, P. Caldwell, N.A. Lunn, A. Drysdale, S.B. Howe, R. Scorrer, T. Gahleitner, F. Gupta, R. Nash, C. Alexander, J. Raman, M. Bell, E. Rajagopal, V. Kohlhoff, S. Cox, E. Zaoutis, T. ARPEC project group
- Abstract
Objectives: Previously, web-based tools for cross-sectional antimicrobial point prevalence surveys (PPSs) have been used in adults to develop indicators of quality improvement. We aimed to determine the feasibility of developing similar quality indicators of improved antimicrobial prescribing focusing specifically on hospitalized neonates and children worldwide. Methods: A standardized antimicrobial PPS method was employed. Included were all inpatient children and neonates receiving an antimicrobial at 8:00 am on the day of the PPS. Denominators included the total number of inpatients. A web-based application was used for data entry, validation and reporting. We analysed 2012 data from 226 hospitals (H) in 41 countries (C) from Europe (174H; 24C), Africa (6H; 4C), Asia (25H; 8C), Australia (6H), Latin America (11H; 3C) and North America (4H). Results: Of 17 693 admissions, 6499 (36.7%) inpatients received at least one antimicrobial, but this varied considerably between wards and regions. Potential indicators included very high broad-spectrum antibiotic prescribing in children of mainly ceftriaxone (ranked first in Eastern Europe, 31.3%; Asia, 13.0%; Southern Europe, 9.8%), cefepime (ranked third in North America, 7.8%) and meropenem (ranked first in Latin America, 13.1%). The survey identified worryingly high use of critically important antibiotics for hospital-acquired infections in neonates (34.9%; range from 14.2% in Africa to 68.0% in Latin America) compared with children (28.3%; range from 14.5% in Africa to 48.9% in Latin America). Parenteral administration was very common among children in Asia (88%), Latin America (81%) and Europe (67%). Documentation of the reasons for antibiotic prescribing was lowest in Latin America (52%). Prolonged surgical prophylaxis rates ranged from 78% (Europe) to 84% (Latin America). Conclusions: Simple web-based PPS tools provide a feasible method to identify areas for improvement of antibiotic use, to set benchmarks and to monitor future interventions in hospitalized neonates and children. To our knowledge, this study has derived the first global quality indicators for antibiotic use in hospitalized neonates and children. © The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
- Published
- 2016
33. Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: Application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data
- Author
-
Bielicki, J.A. Sharland, M. Johnson, A.P. Henderson, K.L. Cromwell, D.A. Berger, C. Esposito, S. Danieli, E. Tenconi, R. Folgori, L. Bernaschi, P. Santiago, B. Saavedra, J. Cercenado, E. Brett, A. Rodrigues, F. Cizman, M. Jazbec, J. Babnik, J. Pavčnik, M. Pirš, M. Mueller Premrov, M. Lindner, M. Borte, M. Lippmann, N. Schuster, V. Thürmer, A. Lander, F. Elias, J. Liese, J. Durst, A. Weichert, S. Schneider, C. Hufnagel, M. Rack, A. Hübner, J. Dubos, F. Lagree, M. Dessein, R. Tissieres, P. Cuzon, G. Gajdos, V. Doucet-Populaire, F. Usonis, V. Gurksniene, V. Bernatoniene, G. Tsolia, M. Spyridis, N. Lebessi, E. Doudoulakakis, A. Lutsar, I. Kõljalg, S. Schülin, T. Warris, A. Antibiotic Resistance Prescribing in European Children project
- Abstract
Objectives: The objective of this study was to evaluate the ability of weighted-incidence syndromic combination antibiograms (WISCAs) to inform the selection of empirical antibiotic regimens for suspected paediatric bloodstream infections (BSIs) by comparing WISCAs derived using data from single hospitals and from a multicentre surveillance dataset. Methods: WISCAs were developed by estimating the coverage of five empirical antibiotic regimens for childhood BSI using a Bayesian decision tree. The study used microbiological data on ~2000 bloodstream isolates collected over 2 years from 19 European hospitals. We evaluated the ability of a WISCA to show differences in regimen coverage at two exemplar hospitals. For each, a WISCA was first calculated using only their local data; a second WISCA was calculated using pooled data from all 19 hospitals. Results: The estimated coverage of the five regimens was 72%-86% for Hospital 1 and 79%-94% for Hospital 2, based on their own data. In both cases, the best regimens could not be definitively identified because the differences in coverage were not statistically significant. For Hospital 1, coverage estimates derived using pooled data gave sufficient precision to reveal clinically important differences among regimens, including high coverage provided by a narrow-spectrum antibiotic combination. For Hospital 2, the hospital and pooled data showed signs of heterogeneity and the use of pooled data was judged not to be appropriate. Conclusions: The Bayesian WISCA provides a useful approach to pooling information from different sources to guide empirical therapy and could increase confidence in the selection of narrow-spectrum regimens. © The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
- Published
- 2016
34. Variation in paediatric hospital antibiotic guidelines in Europe
- Author
-
Spyridis, N. Syridou, G. Goossens, H. Versporten, A. Kopsidas, J. Kourlaba, G. Bielicki, J. Drapier, N. Zaoutis, T. Tsolia, M. Sharland, M. Vergison, A. Léon, V. Delestrait, M. Huza, C. Lepage, P. Mahieu, L. Boy, T. Jansens, H. Van Der Linden, D. Briquet, C. Allegaert, K. Smits, A. Gabriels, P. Vuye, A. Lutsar, I. Tamm, E. Larionova, A. Laan, D. Orbach, M. Lorrot, M. Angoulvant, F. Prot-Labarthe, S. Dubos, F. Lagree, M. Hufnagel, M. Schuster, K. Henneke, P. Roilides, E. Iosifidis, E. Corovessi, V. Michos, A. Galanakis, E. Gkentzi, D. Giacquinto, C. Longo, G. Dona, D. Mion, T. D'Argenio, P. Degli, M.L.C. De Luca, M. Ciliento, G. Esposito, S. Danieli, E. Montinaro, V. Tenconi, R. Nicolini, G. Sviestina, C.I.M. Pavare, J. Rasnaca, K. Gardovska, D. Usonis, V. Grope, I. Gurksniene, V. Eidukaite, A. Biver, A. Brett, A. Esteves, I. Cambrea, S.C. Craiu, M. Tomescu, E. Cizman, M. Babnik, J. Kenda, R. Vidmar, I. Nunez-Cuadros, E. Rojo, P. Lopez-Varela, E. Ureta, N. Perez-Lopez, A. Mosqueda, R. Orta, L. Santos, M. Navarro, M. Santiago, B. Hernandez-Sampelaya, T. Saavedra, J. Pineiro, R. Torel, P. Cano, I.M. Baumann, P. Berger, C. Menson, E. Botgros, A. Doerholt, K. Drysdale, S. Makwana, N. McCorry, A. Garbash, E.M. Chetcutiganado, C. McLeod, M. Caldwell, N. Nash, C. McCullagh, B. Sharpe, D. Tweddell, L. Liese, J.G. Aston, J. Gallagher, A. Satodia, P. Howard-Smith, N. Korinteli, I. Tavchioska, G. Jensen, L. Trethon, A. Unuk, S. Childs, N. Canlas, J.
- Abstract
Objective: To assess the availability and source of guidelines for common infections in European paediatric hospitals and determine their content and characteristics. Design: Participating hospitals completed an online questionnaire on the availability and characteristics of antibiotic prescribing guidelines and on empirical antibiotic treatment including duration of therapy for 5 common infection syndromes: respiratory tract, urinary tract, skin and soft tissue, osteoarticular and sepsis in neonates and children. Results: 84 hospitals from 19 European countries participated in the survey of which 74 confirmed the existence of guidelines. Complete guidelines (existing guidelines for all requested infection syndromes) were reported by 20% of hospitals and the majority (71%) used a range of different sources. Guidelines most commonly available were those for urinary tract infection (UTI) (74%), neonatal sepsis (71%) and sepsis in children (65%). Penicillin and amoxicillin were the antibiotics most commonly recommended for respiratory tract infections (RTIs) (up to 76%), cephalosporin for UTI (up to 50%) and for skin and soft tissue infection (SSTI) and bone infection (20% and 30%, respectively). Antistaphylococcal penicillins were recommended for SSTIs and bone infections in 43% and 36%, respectively. Recommendations for neonatal sepsis included 20 different antibiotic combinations. Duration of therapy guidelines was mostly available for RTI and UTI (82%). A third of hospitals with guidelines for sepsis provided recommendations for length of therapy. Conclusions: Comprehensive antibiotic guideline recommendations are generally lacking from European paediatric hospitals. We documented multiple antibiotics and combinations for most infections. Considerable improvement in the quality of guidelines and their evidence base is required, linking empirical therapy to resistance rates.
- Published
- 2016
35. THE IMMUNE RESPONSE TO HEPATITIS A VACCINE IN CHILDREN WITH PFAPA SYNDROME
- Author
-
Maritsi, D. Vartzelis, G. Spyridis, N. Garoufi, A. and Diamantopoulos, S.
- Published
- 2015
36. THE IMMUNE RESPONSE TO HEPATITIS A VACCINE IN CHILDREN WITH AUTOINFLAMMATORY DISORDERS
- Author
-
Maritsi, D. Vartzelis, G. Metaxa, Z. Vougiouka, O. and Spyridis, N. Diamantopoulos, S.
- Published
- 2015
37. An Infant with Purpuric Rash and Edema
- Author
-
Argyri, I. Korona, A. Mougkou, K. Vougiouka, O. Tsolia, M. Spyridis, N.
- Published
- 2015
38. Interferon gamma inducible protein-10 in the diagnosis of paediatric tuberculosis infection in a low TB incidence country
- Author
-
Amanatidou, V. Critselis, E. Trochoutsou, A. Soldatou, A. Benetatou, K. Spyridis, N. Papadopoulos, N.G. Tsolia, M.N.
- Abstract
OBJECTIVE: To assess interferon-gamma inducible protein 10 (IP-10) as a diagnostic marker for tuberculous infection in children, particularly in relation to its differential diagnostic performance in young children. DES IGN AND RE SULT S: A case-control study was conducted among 161 children and adolescents (mean age 6.3 years 6 standard deviation 1.7; males n = 79, 49%). Fifty-four (33.5%) had active TB, 53 (33%) had latent tuberculous infection (LTBI), and 54 (33.5%) were non-LTBI controls. Unstimulated IP-10 levels did not differ between groups (P > 0.05 for all comparisons). TB-specific antigen stimulated IP-10 levels were more profoundly increased in infected groups than in controls (P < 0.001 for all comparisons). None of the IP-10-based diagnostic indexes demonstrated the ability to discriminate active disease from LTBI. A value of IP-10 ≥ 1222 pg/ml had 83.3% sensitivity, 79.6% specificity, 80.4% positive predictive value and 82.7% negative predictive value for the diagnosis of LTBI. IP-10 based indexes demonstrated a trend towards better performance in the population group aged
- Published
- 2015
39. Antibiotic prescribing and expenditures in outpatient paediatrics in Greece, 2010-13
- Author
-
Kourlaba, G. Kourkouni, E. Spyridis, N. Gerber, J.S. Kopsidas, J. Mougkou, K. Lourida, A. Zaoutis, T.E.
- Abstract
Objectives: The objectives of this study were to provide a nationally representative analysis of antibiotic prescribing in outpatient paediatrics and to assess overall and class-specific antibiotic costs in Greece. Methods: Data on antibiotic prescriptions for patients aged ≤19 years old between July 2010 and June 2013 in Greece were extracted from the IMS Health Xponent database. Antibiotics were grouped into narrow- and broad-spectrum agents. The number of prescribed antibiotics and census denominators were used to calculate prescribing rates. The total costs associated with prescribed antibiotics were calculated. Results: More than 7 million antibiotics were prescribed during the study period, with an annual rate of 1100 antibiotics/1000 persons. Prescribing rates were higher among children aged
- Published
- 2015
40. Antibiotic resistance prevalence in routine bloodstream isolates from children's hospitals varies substantially from adult surveillance data in Europe
- Author
-
Bielicki, Ja, Lundin, R, Sharland, M, Arpec, Project, Berger, C, Esposito, S, Danieli, E, Tenconi, R, Folgori, L, Bernaschi, P, Santiago, B, Saavedra, J, Cercenado, E, Brett, A, Rodrigues, F, Cizman, M, Jazbec, J, Babnik, J, Pavcnik, M, Pirš, M, Premrov, M, Lindner, M, Borte, M, Lippmann, N, Schuster, V, Thürmer, A, Lander, F, Elias, J, Liese, J, Durst, A, Weichert, S, Schneider, C, Hufnagel, M, Rack, A, Hübner, J, Dubos, F, Lagree, M, Dessein, R, Tissieres, P, Cuzon, G, Gajdos, V, Doucet-Populaire, F, Usonis, V, Gurksniene, V, Bernatoniene, G, Tsolia, M, Spyridis, N, Lebessi, E, Doudoulakakis, A, Lutsar, I, Kõljalg, S, Schülin, T, and Warris, A
- Subjects
Microbiology (medical) ,Male ,medicine.medical_specialty ,Surveillance data ,Adolescent ,Klebsiella pneumoniae ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Bacteremia ,age differences ,medicine.disease_cause ,Gram-Positive Bacteria ,Enterococcus faecalis ,Microbiology ,Antibiotic resistance ,Internal medicine ,Streptococcus pneumoniae ,Drug Resistance, Bacterial ,Gram-Negative Bacteria ,medicine ,Prevalence ,Humans ,antimicrobial resistance ,Child ,routine data ,surveillance ,biology ,Pseudomonas aeruginosa ,business.industry ,Age Factors ,Infant, Newborn ,Infant ,biology.organism_classification ,Hospitals, Pediatric ,Anti-Bacterial Agents ,Europe ,Infectious Diseases ,Staphylococcus aureus ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Epidemiological Monitoring ,Female ,business ,Enterococcus faecium - Abstract
Item does not contain fulltext BACKGROUND: Surveillance of antimicrobial resistance (AMR) is central for defining appropriate strategies to deal with changing AMR levels. It is unclear whether childhood AMR patterns differ from those detected in isolates from adult patients. METHODS: Resistance percentages of nonduplicate Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa bloodstream isolates from children less than 18 years of age reported to the Antibiotic Resistance and Prescribing in European Children (ARPEC) project were compared with all-age resistance percentages reported by the European Antimicrobial Resistance Surveillance Network (EARS-Net) for the same pathogen-antibiotic class combinations, period and countries. In addition, resistance percentages were compared between ARPEC isolates from children less than 1 year of age and children greater than or equal to1 year of age. RESULTS: Resistance percentages for many important pathogen-antibiotic class combinations were different for ARPEC isolates compared with EARS-Net. E. coli and K. pneumoniae fluoroquinolone resistance percentages were substantially lower in ARPEC (13.4% and 17.9%) than in EARS-Net (23.0% and 30.7%), whereas the reverse was true for all pathogen-antibiotic class combinations in P. aeruginosa (for example, 27.3% aminoglycoside resistance in ARPEC, 19.3% in EARS-Net, 32.8% carbapenem resistance in ARPEC and 20.5% in EARS-Net), and for S. pneumoniae and macrolide resistance. For many Gram-negative pathogen-antibiotic class combinations, isolates from children greater than or equal to 1 year of age showed higher resistance percentages than isolates from children less than 1 year of age. CONCLUSIONS: Age-stratified presentation of resistance percentage estimates by surveillance programs will allow identification of important variations in resistance patterns between different patient groups for targeted intervention. 01 juli 2015
- Published
- 2015
41. The worldwide antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey: Developing hospital-quality indicators of antibiotic prescribing for children.
- Author
-
Soltani J., Kovacevic T., Nielsen J.P., Petersen J.R., Poorisrisak P., Jensen L.H., Laan M., Tamm E., Matsinen M., Rummukainen M.-L., Gajdos V., Olivier R., Le Marechal F., Martinot A., Prot-Labarthe S., Lorrot M., Orbach D., Pagava K., Hufnagel M., Knuf M., Schlag S.A.A., Liese J., Renner L., Enimil A., Awunyo M., Syridou G., Spyridis N., Critselis E., Kouni S., Mougkou K., Ladomenou F., Gkentzi D., Iosifidis E., Roilides E., Sahu S., Murki S., Malviya M., Kalavalapalli D.B., Singh S., Singhal T., Garg G., Garg P., Kler N., Jafarpour Z., Pouladfar G., Nicolini G., Montagnani C., Galli L., Esposito S., Vecchio A.L., Dona' D., Giaquinto C., Borgia E., D'Argenio P., De Luca M., Centenari C., Raka L., Omar A., Al-Mousa H., Mozgis D., Sviestina I., Burokiene S., Usonis V., Tavchioska G., Hargadon-Lowe A., Zarb P., Borg M.A., Gonzalez Lozano C.A., Castanon P.Z., Cancino M.E., McCullagh B., McCorry A., Gormley C., Al Maskari Z., Al-Jardani A., Pluta M., Rodrigues F., Brett A., Esteves I., Marques L., AlAjmi J.A., Cambrea S.C., Rashed A.N., Al Azmi A.A.M., Chan S.M., Isa M.S., Najdenov P., Cizman M., Unuk S., Finlayson H., Dramowski A., Mate-Cano I., Soto B., Calvo C., Santiago B., Saavedra-Lozano J., Bustinza A., Escosa-Garcia L., Ureta N., Tagarro A., Barrero P.T., Rincon-Lopez E.M., Abubakar I., Aston J., Heginbothom M., Satodia P., Garbash M., Johnson A., Sharpe D., Barton C., Menson E., Arenas-Lopez S., Luck S., Doerholt K., McMaster P., Caldwell N.A., Lunn A., Drysdale S.B., Howe R., Scorrer T., Gahleitner F., Gupta R., Nash C., Alexander J., Raman M., Bell E., Rajagopal V., Kohlhoff S., Cox E., Zaoutis T., Versporten A., Bielicki J., Drapier N., Sharland M., Goossens H., Calle G.M., Clark J., Cooper C., Blyth C.C., Francis J.R., Alsalman J., Jansens H., Mahieu L., Van Rossom P., Vandewal W., Lepage P., Blumental S., Briquet C., Robbrecht D., Maton P., Gabriels P., Rubic Z., Soltani J., Kovacevic T., Nielsen J.P., Petersen J.R., Poorisrisak P., Jensen L.H., Laan M., Tamm E., Matsinen M., Rummukainen M.-L., Gajdos V., Olivier R., Le Marechal F., Martinot A., Prot-Labarthe S., Lorrot M., Orbach D., Pagava K., Hufnagel M., Knuf M., Schlag S.A.A., Liese J., Renner L., Enimil A., Awunyo M., Syridou G., Spyridis N., Critselis E., Kouni S., Mougkou K., Ladomenou F., Gkentzi D., Iosifidis E., Roilides E., Sahu S., Murki S., Malviya M., Kalavalapalli D.B., Singh S., Singhal T., Garg G., Garg P., Kler N., Jafarpour Z., Pouladfar G., Nicolini G., Montagnani C., Galli L., Esposito S., Vecchio A.L., Dona' D., Giaquinto C., Borgia E., D'Argenio P., De Luca M., Centenari C., Raka L., Omar A., Al-Mousa H., Mozgis D., Sviestina I., Burokiene S., Usonis V., Tavchioska G., Hargadon-Lowe A., Zarb P., Borg M.A., Gonzalez Lozano C.A., Castanon P.Z., Cancino M.E., McCullagh B., McCorry A., Gormley C., Al Maskari Z., Al-Jardani A., Pluta M., Rodrigues F., Brett A., Esteves I., Marques L., AlAjmi J.A., Cambrea S.C., Rashed A.N., Al Azmi A.A.M., Chan S.M., Isa M.S., Najdenov P., Cizman M., Unuk S., Finlayson H., Dramowski A., Mate-Cano I., Soto B., Calvo C., Santiago B., Saavedra-Lozano J., Bustinza A., Escosa-Garcia L., Ureta N., Tagarro A., Barrero P.T., Rincon-Lopez E.M., Abubakar I., Aston J., Heginbothom M., Satodia P., Garbash M., Johnson A., Sharpe D., Barton C., Menson E., Arenas-Lopez S., Luck S., Doerholt K., McMaster P., Caldwell N.A., Lunn A., Drysdale S.B., Howe R., Scorrer T., Gahleitner F., Gupta R., Nash C., Alexander J., Raman M., Bell E., Rajagopal V., Kohlhoff S., Cox E., Zaoutis T., Versporten A., Bielicki J., Drapier N., Sharland M., Goossens H., Calle G.M., Clark J., Cooper C., Blyth C.C., Francis J.R., Alsalman J., Jansens H., Mahieu L., Van Rossom P., Vandewal W., Lepage P., Blumental S., Briquet C., Robbrecht D., Maton P., Gabriels P., and Rubic Z.
- Abstract
Objectives: Previously, web-based tools for cross-sectional antimicrobial point prevalence surveys (PPSs) have been used in adults to develop indicators of quality improvement. We aimed to determine the feasibility of developing similar quality indicators of improved antimicrobial prescribing focusing specifically on hospitalized neonates and children worldwide. Method(s): A standardized antimicrobial PPS method was employed. Included were all inpatient children and neonates receiving an antimicrobial at 8:00 am on the day of the PPS. Denominators included the total number of inpatients. A web-based application was used for data entry, validation and reporting. We analysed 2012 data from 226 hospitals (H) in 41 countries (C) from Europe (174H; 24C), Africa (6H; 4C), Asia (25H; 8C), Australia (6H), Latin America (11H; 3C) and North America (4H). Result(s): Of 17 693 admissions, 6499 (36.7%) inpatients received at least one antimicrobial, but this varied considerably between wards and regions. Potential indicators included very high broad-spectrum antibiotic prescribing in children of mainly ceftriaxone (ranked first in Eastern Europe, 31.3%; Asia, 13.0%; Southern Europe, 9.8%), cefepime (ranked third in North America, 7.8%) and meropenem (ranked first in Latin America, 13.1%). The survey identified worryingly high use of critically important antibiotics for hospital-acquired infections in neonates (34.9%; range from 14.2% in Africa to 68.0% in Latin America) compared with children (28.3%; range from 14.5% in Africa to 48.9% in Latin America). Parenteral administration was very common among children in Asia (88%), Latin America (81%) and Europe (67%). Documentation of the reasons for antibiotic prescribing was lowest in Latin America (52%). Prolonged surgical prophylaxis rates ranged from 78% (Europe) to 84% (Latin America). Conclusion(s): Simple web-based PPS tools provide a feasible method to identify areas for improvement of antibiotic use, to set benchmarks and to
- Published
- 2016
42. Variation in paediatric hospital antibiotic guidelines in Europe.
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, UCL - (SLuc) Département de pharmacie, Spyridis, N, Syridou, G, Goossens, H, Versporten, A, Kopsidas, J, Kourlaba, G, Bielicki, J, Drapier, N, Zaoutis, T, Tsolia, M, Sharland, M, ARPEC Project Group Members, Van der Linden, Dimitri, Briquet, Caroline, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, UCL - (SLuc) Département de pharmacie, Spyridis, N, Syridou, G, Goossens, H, Versporten, A, Kopsidas, J, Kourlaba, G, Bielicki, J, Drapier, N, Zaoutis, T, Tsolia, M, Sharland, M, ARPEC Project Group Members, Van der Linden, Dimitri, and Briquet, Caroline
- Abstract
OBJECTIVE: To assess the availability and source of guidelines for common infections in European paediatric hospitals and determine their content and characteristics. DESIGN: Participating hospitals completed an online questionnaire on the availability and characteristics of antibiotic prescribing guidelines and on empirical antibiotic treatment including duration of therapy for 5 common infection syndromes: respiratory tract, urinary tract, skin and soft tissue, osteoarticular and sepsis in neonates and children. RESULTS: 84 hospitals from 19 European countries participated in the survey of which 74 confirmed the existence of guidelines. Complete guidelines (existing guidelines for all requested infection syndromes) were reported by 20% of hospitals and the majority (71%) used a range of different sources. Guidelines most commonly available were those for urinary tract infection (UTI) (74%), neonatal sepsis (71%) and sepsis in children (65%). Penicillin and amoxicillin were the antibiotics most commonly recommended for respiratory tract infections (RTIs) (up to 76%), cephalosporin for UTI (up to 50%) and for skin and soft tissue infection (SSTI) and bone infection (20% and 30%, respectively). Antistaphylococcal penicillins were recommended for SSTIs and bone infections in 43% and 36%, respectively. Recommendations for neonatal sepsis included 20 different antibiotic combinations. Duration of therapy guidelines was mostly available for RTI and UTI (82%). A third of hospitals with guidelines for sepsis provided recommendations for length of therapy. CONCLUSIONS: Comprehensive antibiotic guideline recommendations are generally lacking from European paediatric hospitals. We documented multiple antibiotics and combinations for most infections. Considerable improvement in the quality of guidelines and their evidence base is required, linking empirical therapy to resistance rates.
- Published
- 2016
43. Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia
- Author
-
Tsirigotis, P, primary, Liga, M, additional, Gkirkas, K, additional, Stamouli, M, additional, Triantafyllou, E, additional, Marangos, M, additional, Pessach, I, additional, Sarantopoulos, A, additional, Spyridis, N, additional, and Spyridonidis, A, additional
- Published
- 2016
- Full Text
- View/download PDF
44. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
- Author
-
Katodritou, E. Terpos, E. Kelaidi, C. Kotsopoulou, M. Delimpasi, S. Kyrtsonis, M.-C. Symeonidis, A. Giannakoulas, N. Stefanoudaki, A. Christoulas, D. Chatziaggelidou, C. Gastari, V. Spyridis, N. Verrou, E. Konstantinidou, P. Zervas, K. Dimopoulos, M.A.
- Abstract
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety in PCL. Thus, we retrospectively collected data from 42 consecutive PCL patients (25 with primary PCL-pPCL and 17 with secondary PCL-sPCL) to explore the role of BBR in this entity. BBR were administered in 29 of 42 patients, while 6 of 25 patients with pPCL underwent autologous transplantation. Objective response (≥partial response) was significantly higher in patients treated with BBR versus conventional therapies (69% vs. 30.8%, P=0.04); 27.5% of patients treated with BBR achieved at least very good partial response (vgPR). The highest ORR was observed in pPCL patients treated with BBR (88.9%; ≥vgPR: 33.3%). In BBR-group, grade 3 of 4 hematological, neurological and renal toxicity and neutropenic infections were observed in 41.4%, 7%, 3.4%, and 31%, respectively. With a median follow-up of 51 months, median overall survival (OS) for patients treated with BBR versus conventional therapies was 13 versus 2 months (P
- Published
- 2014
45. Assessment of Hand hygiene resources and practices at the 2 children's hospitals in Greece
- Author
-
Kouni, S. Kourlaba, G. Mougkou, K. Maroudi, S. Chavela, B. Nteli, C. Lourida, A. Spyridis, N. Zaoutis, T. Coffin, S.
- Subjects
education - Abstract
Background: Hand hygiene (HH) is the most effective way to prevent health care-associated infections and the spread of antimicrobial-resistant pathogens. The aim of our study was to assess the existing HH resources and current HH practices at 2 hospitals in Athens, Greece. Methods: Observational HH data and an inventory of HH resources were collected from 13 wards including medical/surgical, oncology/transplant and intensive care units, during 65, 1-hour observations periods. Results: A total of 1271 HH opportunities were observed during the study period, including 944 of Health Care Workers (HCW) and 327 of visitors and parents. The nursing HH compliance was highest (49%) followed by medical compliance (24%, P < 0.001). HCW HH compliance was highest in intensive care units and the transplant unit (64-87%). The rate of appropriate HH for HCW was 22.6%. HCW most commonly used soap and water (76.1%). The HH procedure was more likely to be appropriate when soap and water were used as compared with alcohol based hand rub (64.6% and 47.5%, P = 0.006). A marginally significant association was identified between the HH compliance rate and the number of alcohol based hand rub dispensers per room (P = 0.057). In visitors and parents, the HH compliance was found to be 19%, whereas the rate of appropriate HH was 8.9%. Conclusions: Low levels of HH were observed. Copyright © 2014 by Lippincott Williams & Wilkins.
- Published
- 2014
46. Colonization of high-risk children with carbapenemase-producing enterobacteriaceae in Greece
- Author
-
Mougkou, K. Michos, A. Spyridopoulou, K. Daikos, G.L. Spyridis, N. Syriopoulou, V. Zaoutis, T.
- Published
- 2013
47. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide
- Author
-
Versporten, A, Sharland, M, Bielicki, J, Drapier, N, Vankerckhoven, V, Goossens, H, ARPEC Project Group Members, Cooper, C, Lee, Ly, Whitehouse, J, Bryant, Pa, Haeusler, G, Curtis, N, Starr, M, Vergison, A, Léon, V, Delestrait, M, Huza, C, Lepage, P, Mahieu, L, Boiy, T, Jansens, H, Van der Linden, D, Briquet, C, Allegaert, K, Smits, A, Lutsar, I, Tamm, E, Larionova, A, Orbach, D, Lorrot, M, Angoulvant, F, Doit, C, Prot-Labarthe, S, Dubos, F, Lagree, M, Biscardi, S, Decobert, F, Hau, I, Madhi, F, Durrmeyer, X, Bojang, K, Abubakr, I, Okomo, U, Awe, R, Anderson, S, Akwara, I, Ideh, Rc, Pagava, K, Hufnagel, M, Schuster, K, Henneke, P, Enimil, A, Osei-Akoto, A, Nguah, Sb, Ansong, D, Iosifidis, E, Roilides, E, Spyridis, N, Syridou, G, Soltani, J, Soleimani, N, Nahedi, S, Khosravi, F, Pouladfar, G, Jafarpour, Z, Giacquinto, C, Longo, G, Donà, D, Mion, T, D'Argenio, P, Ciofi Degli Atti ML, De Luca, M, Ciliento, G, Esposito, S, Danieli, E, Montinaro, V, Tenconi, R, Centenari, C, Nicolini, G, Mozgis, D, Sviestina, I, Pavare, J, Rasnaca, K, Gardovska, D, Grope, I, Usonis, V, Gurksniene, V, Eidukaite, A, Biver, A, Bennett, A, O'Hare, B, Kennedy, N, Brett, A, Rodrigues, F, Esteves, I, Cambrea, Sc, Craiu, M, Tomescu, E, Al Shehri MA, Al Shahrani, D, Cizman, M, Babnik, J, Kenda, R, Vidmar, I, Finlayson, H, Rabie, H, Cotton, M, Dramowski, A, Rodrigo, C, Mendez, M, Rojo, P, López-Varela, E, Ureta, N, Mosqueda, R, Pérez-López, A, Orta, L, Santos, M, Navarro, M, Santiago, B, Hernández-Sampelayo, T, Saavedra, J, Bustinza, A, Gil, J, Valls, A, Santesteban, E, Baumann, P, Berger, C, Gifford, A, Menson, E, Botgros, A, Arenas-Lopez, S, Wade, P, Doerholt, K, Drysdale, Sb, Mcelnay, Jc, Kearney, Mp, Scott, Mg, Magee, Fa, Aldeyab, M, Heginbothom, M, Newland, Jg, Hedican, Eb, Shah, H, Stach, L, and Yu, D
- Subjects
Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,medicine.drug_class ,Antibiotics ,MEDLINE ,Drug resistance ,Drug Prescriptions ,point prevalence survey ,antibiotic use ,Antibiotic resistance ,Intensive care ,Drug Resistance, Bacterial ,Medicine ,Humans ,Child ,Electronic Data Processing ,Internet ,business.industry ,Health services research ,Antimicrobial ,antimicrobial use ,Confidence interval ,Drug Utilization ,Hospitals ,Anti-Bacterial Agents ,Europe ,Infectious Diseases ,Pediatrics, Perinatology and Child Health ,surveillance ,hospitalized children ,Health Services Research ,business ,Public Health Administration - Abstract
Background The neonatal and pediatric antimicrobial point prevalence survey (PPS) of the Antibiotic Resistance and Prescribing in European Children project (http://www.arpecproject.eu/) aims to standardize a method for surveillance of antimicrobial use in children and neonates admitted to the hospital within Europe. This article describes the audit criteria used and reports overall country-specific proportions of antimicrobial use. An analytical review presents methodologies on antimicrobial use. Methods A 1-day PPS on antimicrobial use in hospitalized children was organized in September 2011, using a previously validated and standardized method. The survey included all inpatient pediatric and neonatal beds and identified all children receiving an antimicrobial treatment on the day of survey. Mandatory data were age, gender, (birth) weight, underlying diagnosis, antimicrobial agent, dose and indication for treatment. Data were entered through a web-based system for data-entry and reporting, based on the WebPPS program developed for the European Surveillance of Antimicrobial Consumption project. Results There were 2760 and 1565 pediatric versus 1154 and 589 neonatal inpatients reported among 50 European (n = 14 countries) and 23 non-European hospitals (n = 9 countries), respectively. Overall, antibiotic pediatric and neonatal use was significantly higher in non-European (43.8%; 95% confidence interval [CI]: 41.3-46.3% and 39.4%; 95% CI: 35.5-43.4%) compared with that in European hospitals (35.4; 95% CI: 33.6-37.2% and 21.8%; 95% CI: 19.4-24.2%). Proportions of antibiotic use were highest in hematology/oncology wards (61.3%; 95% CI: 56.2-66.4%) and pediatric intensive care units (55.8%; 95% CI: 50.3-61.3%). Conclusions An Antibiotic Resistance and Prescribing in European Children standardized web-based method for a 1-day PPS was successfully developed and conducted in 73 hospitals worldwide. It offers a simple, feasible and sustainable way of data collection that can be used globally.
- Published
- 2013
48. Trends in the epidemiology of childhood tuberculosis in Greece
- Author
-
Syridou, G. Mavrikou, M. Amanatidou, V. Spyridis, N. Prasad, P. Papaventsis, D. Kanavaki, S. Zaoutis, Th. Tsolia, M.N.
- Abstract
SETTING: A hospital referral center for childhood tuberculosis (TB). OBJECTIVE: To evaluate the epidemiological and clinical features of childhood TB in the Greater Athens area in the last decade. DESIGN: We retrospectively reviewed the medical rec ords of patients aged
- Published
- 2012
49. Impact of the gen-probe amplified MTD® test on tuberculosis diagnosis in children
- Author
-
Papaventsis, D. Ioannidis, P. Karabela, S. Nikolaou, S. Syridou, G. Marinou, I. Konstantinidou, E. Amanatidou, V. Spyridis, N. Kanavaki, S. Tsolia, M.
- Abstract
OBJECTIVE: To evaluate the performance of the Gen- Probe Amplified MTD® Test (AMTD) for childhood tuberculosis (TB) diagnosis compared to conventional culture. DESIGN: We retrospectively studied 121 childhood cases (73 males; median age 7 years, range 1-16). Pulmonary samples (104/152, 68%) included gastric aspirates (n = 53), induced sputum samples (n = 43), bronchial aspirates and bronchoalveolar lavage (n = 8). Extrap ulmonary samples (48/152, 32%) included lymph nodes (n = 34) and other sterile fluids (n = 14). Specimens were examined using acid-fast bacilli (AFB) microscopy, AMTD and bacterial culture using BACTECTM MGITTM 960 and Löwenstein-Jensen (LJ) media. RESULTS: A clinical diagnosis of TB was made in 50/121 (41%) children (43/50 pulmonary disease). AFB microscopy was positive in 6%; Mycobacterium tuberculosis was recovered by culture from 16/50 (32%) and AMTD was positive in 29/50 (58%). AMTD sensitivity, specificity, positive predictive value and negative predictive value compared to culture were respectively 100%, 85%, 50% and 100%. For pulmonary vs. extrapulmonary disease, the performance of AMTD compared to culture was respectively 100%, 77%, 46% and 100% vs. 100%, 97.5%, 75% and 100%. CONCLUSIONS: Nucleic acid amplification tests are more sensitive and very specific methods for the rapid detection of M. tuberculosis. The AMTD technique increases TB detection in children compared to conventional culture. © 2012 The Union.
- Published
- 2012
50. Comparing neonatal and paediatric antibiotic prescribing between hospitals: A new algorithm to help international benchmarking
- Author
-
Porta, A. Hsia, Y. Doerholt, K. Spyridis, N. Bielicki, J. Menson, E. Tsolia, M. Esposito, S. Wong, I.C.K. Sharland, M.
- Abstract
Objectives: The WHO anatomical therapeutic chemical (ATC)/defined daily dose (DDD) methodology is a standardized method of comparing antimicrobial use. The ATC/DDD is defined as the average maintenance daily dose of a drug used in a 70 kg adult, ignoring the considerable differences in body weight of neonates and children. The aim of this study was to develop a new standardized way of comparing rates of antimicrobial prescribing between European children's hospitals. Methods: This pilot study at four European children's hospitals (in the UK, Greece and Italy) collected data including demographics, antibiotic use, dosing and indication in children and neonates over a 14 day period. Results: A total of 1217 antibiotic prescriptions were issued with 47 different antibiotics used. Approximately half of all children and a third of all neonates received antibiotics, with wide variation between centres in the type and dose of antibiotic used. We propose a new pragmatic three-step algorithm. The first step includes a simple comparison of the proportion of hospitalized children on antibiotics by weight bands and the number of antimicrobials that account for 90% of total DDD drug usage (DU90%). The second step is a comparison of the dosing used (mg/kg/day). The third step is to compare overall drug exposure using DDD/100 bed days for standardized weight bands between centres. Conclusions: This novel method has the potential to be a useful tool to provide antibiotic use comparator data and requires validation in a large prospective point prevalence study. © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.